Elranatamab Improves MRD Negativity After CAR T Therapy
News Context
At a glance
- Note: the dates in reference 2 (July 15, 2025 and September 22, 2025) are in the future, which is unusual.
HereS a breakdown of the references provided, formatted for clarity:
- Clinical Trial: Large real-world study validates idecabtagene vicleucel outcomes seen in KarMMa trial. https://clinicaltrials.gov/study/NCT06138275
- Gerlach A. Pharmacy Times. Large real-world study validates idecabtagene vicleucel outcomes seen in KarMMa trial. July 15, 2025. Accessed September 22, 2025. https://www.pharmacytimes.com/view/large-real-world-study-validates-idecabtagene-vicleucel-outcomes-seen-in-karmma-trial
- clinical Trial: Efficacy and safety study of bb2121 in subjects with relapsed and refractory multiple myeloma (KarMMa). Clinicaltrials.gov identifier: NCT033617 (Incomplete – the identifier is cut off).
Note: the dates in reference 2 (July 15, 2025 and September 22, 2025) are in the future, which is unusual. It’s possible there’s an error in the provided text. Also, reference 3 is incomplete.